证券代码：300110 证券简称：华仁药业 公告编号：2025-033 华仁药业股份有限公司 2024 年度股东大会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决提案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）于2025年4 月23日在巨潮资讯网披露了《关于召开2024年度股东大会的通知》（公告编号： 2025-022），并于2025年4月29日在巨潮资讯网披露了《关于2024年度股东大会 增加提案的公告暨召开2024年度股东大会的补充通知》（公告编号：2025-028）。 2、会议召开时间： （1）现场会议召开时间：2025年5月14日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年5月14日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025年5月14日上午9:15-下午15: ...

华仁药业股份有限公司 章 程 二〇二五年五月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | | 第一节 股份发行 2 | | 第二节 | 股份增减和回购 3 | | | 第三节 股份转让 4 | | 第四章 | 股东和股东大会 5 | | | 第一节 股东 5 | | | 第二节 股东大会的一般规定 9 | | | 第三节 股东大会的召集 11 | | | 第四节 股东大会的提案与通知 12 | | | 第五节 股东大会的召开 14 | | | 第六节 股东大会的表决和决议 17 | | 第五章 | 董事会 22 | | | 第一节 董事 22 | | | 第二节 董事会 26 | | 第六章 | 总裁及其他高级管理人员 32 | | 第七章 | 监事会 34 | | | 第一节 监事 34 | | | 第二节 监事会 35 | | 第八章 | 党建工作 36 | | 第一节 | 党组织的机构设置 36 | | 第二节 | 公司党委 37 | | 第三节 | 公司纪委 38 | | 第九章 | 财务会计制度、利润分配和审计 ...

股票代码：300110 股票简称：华仁药业 编号：2025-002 | 投资者关系活动类 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | ☑其他 （2025 | 年青岛辖区上市公司投资者网上集体接 | | | 待日活动） | | | 参与单位名称及人 | 线上参与华仁药业 | 2025 年青岛辖区上市公司投资者网 | | 员姓名 | 上集体接待日活动的投资者 | | | 时间 | 年 月 2025 5 12 | 日（星期一）下午 15:00-17:00 | | 地点 | "全景路演"网站（http://rs.p5w.net） | | | 上市公司接待人员 | 董事长：张力先生 | | | 姓名 | 总裁：李健先生 | | | | 独立董事：刘勇先生 | | | | 财务总监：韩莉萍女士 | | | | 董事会秘书：冯新光先生 1、看好公司未来发展，股价这么低，有回购的计划吗？ | | | | 尊敬的投资者您好，公司将持续贯彻转型升级发展战 | | | | ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-032 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"一次性滑移垫"的《医疗器械注 册证》，现将相关情况公告如下： 8、注册分类：Ⅱ类 9、批准日期：2025 年 4 月 23 日 10、有效期至：2030 年 4 月 22 日 一、医疗器械基本情况 1、注册人名称：青岛华仁医疗用品有限公司 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号无菌医疗器械车间楼 4、产品名称：一次性滑移垫 5、型号、规格：I 型、Ⅱ型、Ш 型、Ⅳ型、V 型、Ⅵ型 6、适用范围：用于医疗机构运送、移动患者用 7、注册证编号：鲁械注准 20252150222 二〇二五年五月六日 二、医疗器械相关情况 公司本次获得二类医疗器械注册证的一次性滑移垫用于医疗机构运送、移动 患者用，产品包含 6 个型号规格 ...

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

证券代码：300110 证券简称：华仁药业 公告编号：2025-031 华仁药业股份有限公司 红塔创新于本次减持计划期间累计减持公司股份 11,819,960 股，该股份来源 于公司首次公开发行股票前其持有的股份，均已解除限售。减持股份具体情况如 下： | 股东 | 股份 | 减持 | 减持期间 | 减持均价 | 减持股数 | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 性质 | 方式 | | （元） | (股） | （%） | | 红塔创 | 无限售 条件股 | 集中竞 | 2025.4.14- | 3.00 | 11,819,960 | 1.00 | | 新 | | 价 | 2025.4.29 | | | | | | 份 | | | | | | 二、红塔创新本次减持前后持股情况 | | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 股东 | 股份 | | | | | | 名称 | 性质 | 股数（股） | 占总股本 | 股数（股） | 占总股 ...

Core Viewpoint - Huaren Pharmaceutical (300110) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has received the "Medical Device Registration Certificate" for "Medical Wound Dressings" from the Shandong Provincial Drug Administration, which will enhance the company's product line and competitiveness in the medical device sector [1] Group 1 - The newly approved product is suitable for non-chronic wounds and surrounding skin care, comprising 15 different specifications [1] - There are currently 22 companies in the domestic market with similar listed products, indicating a competitive landscape [1] - The acquisition of this registration certificate will support the synergistic development of the company's segments, including raw materials, formulations, medical devices, and medical packaging [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-029 华仁药业股份有限公司 关于参加 2025 年青岛辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华仁药业股份有限公司（以下简称"公司"） 将参加由青岛证监局指导、青岛市上市公司协会与深圳市全景网络有限公司联合 举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现将相关事项公 告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。届 时公司董事长张力先生、总裁李健先生、独立董事刘勇先生、财务总监韩莉萍女 士及董事会秘书冯新光先生将以在线交流形式就公司治理、发展战略、经营状况 和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大投资者踊 跃参与! 特此公告。 华仁药业股份有限公司董事会 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-030 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"医用创面敷料"的《医疗器械注 册证》，现将相关情况公告如下： 一、医疗器械基本情况 1、注册人名称：青岛华仁医疗用品有限公司 2、注册人住所：青岛市崂山区株洲路 187 号 3、生产地址：青岛市崂山区株洲路 187 号 2 号楼、无菌医疗器械车间楼 4、产品名称：医用创面敷料 5、产品型号、规格：型号：圆型、方型、椭圆型；规格：10g/片、15g/片、 20g/片、25g/片、30g/片 6、适用范围：适用于非慢性创面（如浅表性创面、激光/光子/果酸换肤后的 创面）及周围皮肤的护理 7、注册证编号：鲁械注准 20252140226 8、注册分类：Ⅱ类 9、批准日期：2025 年 4 月 23 日 10、有效期至：2030 年 4 月 22 日 二、医疗器械相关情况 ...